肿瘤浸润淋巴细胞为低危导管原位癌患者提供额外预后信息:SweDCIS随机放疗试验发现
本文为SweDCIS随机放疗试验的事后分析,纳入保乳术后原发性导管原位癌(DCIS)病例,按国际免疫肿瘤生物标志物工作组指南在苏木精-伊红切片上评估肿瘤浸润淋巴细胞(TILs,n=711)。高TILs与术后5年同侧乳腺事件累积发生率升高相关(TILs低者9% vs TILs高者18%,p<0.001),在HER2阴性DCIS中高TILs为独立不良预后因素(校正HR 2.41,95%CI 1.17-4.95,p=0.017),未检出TILs与放疗获益的交互作用。
要点
- 61.9%的女性TILs≤5%;高TILs与更大病灶、HER2阳性、更高核级别及KI67评分相关。
- 术后5年同侧乳腺事件累积发生率TILs低者9% vs TILs高者18%(p<0.001)。
- HER2阴性DCIS中高TILs为同侧乳腺事件独立不良预后因素,校正HR 2.41(95%CI 1.17-4.95,p=0.017)。
核心结论
- 高TILs与术后5年更高的同侧乳腺事件风险相关,尤其在HER2阴性DCIS中。
- 作者认为应将TILs纳入临床评估,以界定可省略辅助治疗的低危DCIS患者或可能从免疫治疗获益的患者。
研究设计与样本
- SweDCIS随机放疗试验的事后分析,纳入保乳术后原发性DCIS病例。
- 按国际免疫肿瘤生物标志物工作组指南在苏木精-伊红切片上评估TILs(n=711)。
- TILs评分作为连续变量及二分类变量(≤5% vs >5%)分析,预设主要终点为同侧乳腺事件(IBEs)。
主要发现
- 多数女性(61.9%)TILs≤5%。
- 高TILs评分与更大病灶尺寸、HER2阳性、更高核级别及KI67评分相关。
- 术后5年同侧乳腺事件累积发生率TILs低者9% vs TILs高者18%(p<0.001)。
- HER2阴性DCIS中,多因素分析显示高TILs为同侧乳腺事件风险的独立不良预后标志,校正HR 2.41(95%CI 1.17-4.95,p=0.017)。
- 纳入TILs状态可对总体低危DCIS患者(分级<3、尺寸<25 mm、切缘阴性)进行更精细分层;未检出TILs与放疗获益之间的交互作用。
临床怎么用
- 作者认为应将TILs纳入临床评估,以界定可省略辅助治疗的低危DCIS患者或可能从免疫治疗获益的患者。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The immune microenvironment is an important modulator of tumour progression and treatment response. In invasive breast cancer, assessment of tumour-infiltrating lymphocytes (TILs) provides prognostic and predictive information. However, the clinical impact of TILs for ductal carcinoma in situ (DCIS) has not yet been demonstrated. PATIENTS AND METHODS: Post hoc analysis of the SweDCIS randomised radiotherapy trial including primary DCIS cases following breast-conserving surgery. TILs were assessed on haematoxylin-eosin sections (n = 711) according to the International Immuno-Oncology Biomarker Working Group guidelines. TILs-scores were analysed as continuous and dichotomised (≤5% versus >5%) variable regarding ipsilateral breast events (IBEs) as the predefined primary endpoint. RESULTS: Most women (61.9%) showed a TILs prevalence of ≤5%. High TILs-scores were associated with larger lesion size, human epidermal growth factor receptor 2 (HER2)-positivity, higher nuclear grade, and KI67-score. DCIS cases with high TILs prevalence had a significant increased cumulative IBE incidence at five years post-surgery (TILslow-versus TILshigh 9% versus 18%; p < 0.001). Among patients with HER2-negative DCIS, high TILs remained an independent poor prognosis marker for IBE risk in multivariable analysis with an adjusted hazard ratio of 2.41 [95%CI 1.17-4.95, p = 0.017]. Including TILs-status provided a refined stratification of patients with general low-risk DCIS (grade <3, size <25 mm, free margin). No interaction between TILs and radiotherapy benefits was detected. CONCLUSION: High TILs are associated with higher IBE risk over 5-years post-surgery, particularly for HER2-negative DCIS. Our data indicate that TILs should be integrated into the clinical workup to define patients with low-risk DCIS who can omit adjuvant therapy or patients with potential benefits from immunotherapy.
引用
- Schiza A, Thurfjell V, Stenmark Tullberg A, et al. Tumour-infiltrating lymphocytes add prognostic information for patients with low-risk DCIS: findings from the SweDCIS randomised radiotherapy trial. Eur J Cancer. 2022. PMID: 35236568. doi:10.1016/j.ejca.2022.01.016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。